# Recursion Aligns With FDA on Late-Stage Trial Design for REC-4881

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/60699
Published: 2026-11-18T17:50:46.000Z
Updated: 2026-11-18T17:50:46.000Z
Section: Business

> Recursion described the program as an early example of AI-assisted drug discovery pursuing a design intended to support registration.

Recursion Pharmaceuticals said Nov. 18 that it aligned with the FDA on a late-stage trial design for REC-4881, a rare-disease therapy candidate.

Recursion described REC-4881 as an early example of AI-assisted drug discovery advancing toward a trial design intended to support registration.


